Physician profile
David M Fastenberg
NPI 1336252626
$2,867.30
in general payments reported to CMS, 2019-2025
14 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $179 · 2021: $218 · 2022: $321 · 2023: $678 · 2024: $479 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $918.80 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $790.38 | 2019-2025 | Vabysmo |
| Coherus Oncology, INC. | $182.92 | 2023 | |
| Allergan, INC. | $178.63 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $119.32 | 2019 | |
| Abbvie INC. | $118.91 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $114.76 | 2022-2025 | Syfovre |
| Asd Specialty Healthcare, LLC | $104.50 | 2019 | |
| Alimera Sciences, INC. | $99.14 | 2019-2024 | Iluvien, Yutiq |
| Genentech, INC. | $92.84 | 2020 | |
| Sandoz INC. | $76.47 | 2024 | Cimerli |
| Mallinckrodt Hospital Products INC. | $30.75 | 2024 | Acthar |
| Eyepoint US, INC. | $25.96 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fastenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.